Indications
Qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. The use of Qdenga should be in accordance with official recommendations.
Composition
- Active substance
- Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated
- International name (INN)
- dengue tetravalent vaccine (live, attenuated)
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Qdenga
- ATC code
- J07BX04